Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Itsmore
Fosun Xingmai is a scientific and technological innovation-oriented enterprise focusing on the research and development, production and sales of medical imaging and pathological artificial intelligence software and digital solutions. Its products mainly analyze medical images through the use of artificial intelligence technology.
UniXell
Seed Round in 2022
UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.
Yuesai Biotechnology is a cell therapy drug developer that uses human pluripotent stem cell technology. Yuesai Biotechnology develops stem cell therapy for neurodegenerative diseases, rare diseases, and tumors using its proprietary intellectual property rights of human pluripotent stem cell preparation, cultivation, differentiation, and gene editing technology platform.
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality. MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality. MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.
Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.
EOS imaging is a medical company revolutionizing the treatment continuum for the most common osteoarticular conditions (hip, knee and spine) and associated orthopedic surgeries. Its EOS® 2D/3D imaging system is specifically adapted to the needs of orthopedic surgeons and radiologists. This personalized imaging tool gives a precise 3D image of the patient's skeleton in the upright position that can be used to inform all aspects of care. The Company has obtained authorization to market the system in 48 countries. The Company is based in Paris, with a subsidiary in the United States in Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.
Glycotest Diagnostics is developing unique and non-invasive blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis. Our technology could revolutionize care and treatment for groups at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease. Over 25 million people in the US, 800 million worldwide, and another 1.2 billion in jeopardy due to fatty liver disease may benefit from Glycotest’s products.
Butterfly has created the world's first handheld, single-probe whole-body ultrasound system using its patented Ultrasound-on-Chip™ semiconductor technology. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly is paving the way for earlier detection and remote management of health conditions around the world.
Fushoukang is a home medical care services organization. They offer home medical care, nursing, and rehabilitation services. They provide long term services, institutional care, home care, smart home beds, and hospitcal escorts for the healthy self care elderly, semin disabled elderly , sick elderly, and demented elderly, and more services.
Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China.
Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters, and novel mAbs using cutting-edge technology. The company is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, formed in 2009. It is headquartered in the Shanghai Caohejing High-Technology Park.
LinkedCare is a consumer medical digital service platform that provides integrated operation and management solutions for consumer medical enterprises such as dental clinics and aesthetic medical institutions, and assists institutions in realizing management standardization, diagnosis and treatment standardization, marketing socialization, mobile office, and decision-making data standardization. LinkedCare fully automates the digital operation of consumer medical institutions, assisting them to complete the closed loop of health management that increases revenue, avoids risks, lowers expenditures, and improves efficiency.
Tridem Pharma operates as a pharmaceutical distribution and promotion company. Tridem Pharma is expert in the distribution of pharmaceutical and parapharmaceutical products in Africa.
Breas Medical AB, a member of the GE Healthcare group, was founded in Gothenburg, Sweden in 1991 and has continued to expand during two decades. Our product development programme is focused on home care ventilation and sleep therapy products for the individual patient. Products are sold worldwide either through Breas or other GE Healthcare companies, or through a network of highly trained distributors.
Sinopharm Online has a pharmaceutical retail platform to provide users with online medication consultation, medical and health management consulting services, etc. The main sales cover Chinese and Western medicines and health products. , medical equipment, Chinese medicine
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.
Gland Pharma Limited is a manufacturer and marketer specializing in injectable-focused generic liquid parenteral products. Established in 1978 in Hyderabad, India, the company has developed a diverse portfolio of key molecules, including heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections. Its product range spans various therapeutic categories such as anti-infectives, anesthetics, anti-coagulants, oncology, and more. Gland Pharma is particularly recognized for its expertise in small volume parenterals and has pioneered heparin technology in India, becoming a leader in glycosaminoglycans. The company primarily serves regulated markets, with a significant share of its business coming from the United States, Canada, Europe, and Australia. In addition to its manufacturing capabilities, Gland Pharma offers contract development and manufacturing services to global partners, reinforcing its commitment to high-quality injectable products. As of October 2017, Gland Pharma operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1.
Spirosure develops breath-analysis devices to apply novel breath-based analysis in disease diagnosis and management. Their breath-analysis devices focus on providing non-invasive products for the management of chronic diseases including asthma, COPD, and chronic pulmonary hypertension using a nexus of consumer technologies for preventative healthcare through sensors and algorithms. They enable medical researchers to detect biomarkers in a patient's breath to diagnose and monitor respiratory conditions.
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.
company that was founded in 2007 by a group of healthcare investors. The company has a focus on the development, manufacture and sale of high quality generic pharmaceutical products for two of the most important markets in the world…the United States and China. Our US office is located in central New Jersey. In addition to executive management, this location also houses staff in the following functions for the US market: product and business development, finance, regulatory affairs, and commercial operations. Product development is being undertaken at various locations around the world under the supervision of its experienced R&D, quality, and regulatory leaders.
Check-Cap is a young and dynamic medical device company with breakthrough solution for Colorectal Cancer Screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy.
Chindex International, Inc. provides healthcare services in China. The company owns and operates the United Family Healthcare network of private primary care hospitals and affiliated ambulatory clinics in Beijing, Shanghai, Tianjin, and Guangzhou. The company was founded in 1981 and is headquartered in Bethesda, Maryland.
BSC develops a series of software and hardware products. They provide teleconsultation, remote video, remote ECG, telepathology, distance education, and remote ultrasound services.
Saladax develops rapid blood tests for point-of-care and for laboratory analyzers for use in psychiatry and oncology. The firm has been supplying laboratories and clinicians worldwide with revolutionary diagnostic solutions for more than 15 years.
Laoniangjiu Catering is a food and beverage company. They offer a business takeaway menu with staple meals, beverages, desserts, delicious soups, and breakfast snacks. They provide chinese-style fast food products that are mainly flavored and can be superimposed on food and beverages.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.